Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
A phase 2 trial of AL8326 40 mg in small-cell lung cancer, renal cell carcinoma and non-small-cell lung cancer, run by Advenchen Pharmaceuticals, LLC., now recruiting.
Overview
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment is a phase 2 interventional study registered as NCT05363280 by Advenchen Pharmaceuticals, LLC., with 80 participants planned, started 2022-11-01 and due to reach its primary completion in 2027-12. Interventions recorded: AL8326 40 mg, AL8326 60 mg and AL8326 80 mg--stopped.
Similar pages
not linked directly; found by shared links- TrialA Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.
Shares Advenchen Laboratories and the tag pipeline.
- TreatmentAL8326
Shares Renal cell carcinoma, Small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
- TrialA Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
Shares Renal cell carcinoma, Small-cell lung cancer and the tag pipeline.
- TrialA Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Shares Renal cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
- TrialTT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
Shares Renal cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Shares Renal cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
- TrialA Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
Shares Renal cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
- TrialStudy of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Shares Renal cell carcinoma and the tag pipeline.